Evidence map›Paper›PMID 42872256›Full record

ArticleNeuropsychiatric disease and treatment2026

Treatment Goals in Schizophrenia as Seen by Matched Patients and Physicians: Preferences and Medication Formulation Strategies.

Bernhard T Baune, Wolfgang Janetzky

Abstract read
In one paragraph

Article in Neuropsychiatric disease and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Bernhard T BauneDepartment of Psychiatry, University of Münster, Münster, Germany.ORCID 0000-0001-6548-426X
Wolfgang JanetzkyLundbeck GmbH, Hamburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: In the treatment of schizophrenia, it is important that physicians and patients discuss treatment goals and measures to reach these, including medication formulations (oral or long-acting injectable, LAI). Methods: A survey was conducted in matched pairs of patients with schizophrenia and their treating psychiatrists. The questionnaires contained treatment goals that were rated by the participants, along with questions about oral and LAI medication. Study objectives were to rank treatment goals from a patient's and psychiatrist's perspective, assess the psychiatrist's and patient's choice of oral antipsychotic vs LAI to reach the goals, and assess concordance of treatment goals and treatment choice between psychiatrists and patients. Results: Responses from 43 physician-patient pairs involving 14 individual physicians (0.9% of contacted physicians) were received. Treatment goals were rated equally for a large proportion (39-71%) of physician-patient pairs in the goal categories "effectiveness/symptom reduction" and "quality of life/functioning/participation", but less so for the category "tolerability" (30-56%), which appeared more important to patients. The majority of surveyed patients preferred oral medication, while physicians tended to perceive oral and LAI medication as equally suitable. Conversations about LAIs were more frequent if patients had already tried LAI. Conclusions: Patients tended to have a stronger focus on avoiding side effects than their physicians and seemed to prefer oral medication to reach their goals. Our results come from a small convenience sample with low response rate and should be interpreted as exploratory. Still, there may be room for improvement of physician-patient conversations.

Indexed as

long-acting injectableoral antipsychoticpatient centeredschizophreniatreatment goal

Identifiers

PMID42872256
PMCPMC13660839

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.